Abstract: The present disclosure provides technologies for target entity detection. One aspect of the present disclosure provides technologies for detection (e.g., early detection) of a disease, disorder, or condition (e.g., cancer). In another aspect, technologies provided herein are useful for selecting and/or monitoring and/or evaluating efficacy of, a treatment administered to a subject in need thereof, e.g., a subject determined to have or susceptible to cancer. In some embodiments, technologies provided herein are useful for development of companion diagnostics, e.g., by measuring tumor burdens and changes in tumor burdens in conjunction with therapeutics.
Type:
Grant
Filed:
February 28, 2020
Date of Patent:
August 10, 2021
Assignee:
Mercy BioAnalytics, Inc.
Inventors:
Joseph Charles Sedlak, Laura Teresa Bortolin, Daniel Parker Salem